Regulatory networks defining EMT during cancer initiation and progression
Open accessThe DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.
Abstract
Epithelial to mesenchymal transition (EMT) is essential for driving plasticity during development, but is an unintentional behaviour of cells during cancer progression. The EMT-associated reprogramming of cells not only suggests that fundamental changes may occur to several regulatory networks but also that an intimate interplay exists between them. Disturbance of a controlled epithelial balance is triggered by altering several layers of regulation, including the transcriptional and translational machinery, expression of non-coding RNAs, alternative splicing and protein stability.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In cancer, EMT plays an important role in tumor invasion, metastasis, and resistance to various therapies [75].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [75]
Citations
Cites
1 retracted
RETRACTED: Lysyl Oxidase-like 2 Deaminates Lysine 4 in Histone H3
Herranz, N., Dave, N., Millanes‐Romero, A., Morey, L., Diaz, V. M., Lorenz, V., Gallego, R. G., Jerónimo, C., Croce, L. D., de Herreros, A. G., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.03.002 · Cited by 80
RetractedEpithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004) · Cell · doi:10.1016/j.cell.2004.06.006 · Cited by 3,855
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., & García de Herreros, A. (2000) · Nature Cell Biology · doi:10.1038/35000034 · Cited by 2,666
Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008) · Genes & Development · doi:10.1101/gad.1640608 · Cited by 2,272
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136
Cited by
Items 201–300 of 1,004
Role of cell–cell adhesion complexes in embryonic stem cell biology
Pieters, T., & Roy, F. M. V. (2014) · Journal of Cell Science · doi:10.1242/jcs.146720 · Cited by 141
“EMT is regulated by extracellular cues, such as transforming growth factor b 1 (TGFb1), transcription factors (Snail, Slug, ZEB1, ZEB2 and Twist), microRNAs and epigenetic modulations (De Craene and Berx, 2013).”
BackgroundMekhdjian, A. H., Kai, F., Rubashkin, M. G., Prahl, L. S., Przybyla, L., McGregor, A., Bell, E. S., Barnes, J. M., DuFort, C. C., Ou, G., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-09-0654 · Cited by 148
“…potential may reside in the observation that metastatic tumor cells often exhibit traits consistent with an epithelial-to-mesenchymal transition (EMT)—a developmental process that is often hijacked by cancer cells (Egeblad et al., 2010; Taube et al., 2010; Craene and Berx, 2013; Jung et al., 2015).”
BackgroundJung, H., Fattet, L., Tsai, J. H., Kajimoto, T., Chang, Q., Newton, A. C., & Yang, J. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0291-8 · Cited by 153
TGFβ and matrix-regulated epithelial to mesenchymal transition
Moustakas, A., & Heldin, P. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.02.004 · Cited by 131
Clapéron, A., Mergey, M., Ho-Bouldoires, T. H. N., Vignjevic, D. M., Wendum, D., Chrétien, Y., Merabtene, F., Frazao, A., Paradis, V., Housset, C., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.033 · Cited by 132
Diepenbruck, M., Waldmeier, L., Ivanek, R., Berninger, P., Arnold, P., van Nimwegen, E., & Christofori, G. (2014) · Journal of Cell Science · doi:10.1242/jcs.139865 · Cited by 132
“Furthermore, we identified other candidate Tead2 target genes that had been previously implicated in EMT and/or malignant tumor progression (De Craene and Berx, 2013; Polyak and Weinberg, 2009; Tiwari et al., 2012), such as Amotl2, Esrp2, Mal, Pdfgc, Serpine1 and others (supplementary material…”
BackgroundSeptins promote stress fiber–mediated maturation of focal adhesions and renal epithelial motility
Dolat, L., Hunyara, J. L., Bowen, J. R., Karasmanis, E. P., Elgawly, M., Galkin, V. E., & Spiliotis, E. T. (2014) · The Journal of Cell Biology · doi:10.1083/jcb.201405050 · Cited by 159
Long non-coding RNA regulation of epithelial–mesenchymal transition in cancer metastasis
Xu, Q., Deng, F., Qin, Y., Zhao, Z., Wu, Z., Xing, Z., Ji, A., & Wang, Q. J. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.149 · Cited by 136
“Concomitantly, mesenchymal marker proteins, such as N-cadherin, P-cadherin, fibronectin, and intermediate filament protein vimentin, are frequently overexpressed and contribute to cell migration as well as invasion-associated gene expression in different types of cancer.(5) The most important regulators of cell adhesi…”
BackgroundPartial EMT in head and neck cancer biology: a spectrum instead of a switch
Pal, A., Barrett, T. F., Paolini, R. L., Parikh, A. S., & Puram, S. V. (2021) · Oncogene · doi:10.1038/s41388-021-01868-5 · Cited by 143
“est in MET, whereby metastatic mesenchymal cells might embrace an epithelial program which enables post-seeding tumor growth at secondary sites [33, 34].”
BackgroundWnt and FGF mediated epithelial‐mesenchymal crosstalk during lung development
Volckaert, T., & De Langhe, S. P. (2015) · Developmental Dynamics · doi:10.1002/dvdy.24234 · Cited by 130
“…as observed in cancer cells, which entails the loss of apicobasal cell polarity and destabilization of junctional complexes (Thiery et al., 2009; De Craene and Berx, 2013), is instrumental for the acquisition of stemness by nontransformed and tumor cells (Mani et al., 2008; Guo et al., 2012) and…”
BackgroundLee, J., & Kong, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2313-z · Cited by 137
“Notably, during EMT and MET, the expression of the EMT marker E-cadherin, which is regarded as a tumor suppressor, is regulated by multiple enzymes involving epigenetic modifications [11, 12].”
BackgroundJensen, D., Dabelsteen, E., Specht, L., Fiehn, A. K., Therkildsen, M. H., Jønson, L., Vikesaa, J., Nielsen, F. C., & von Buchwald, C. (2015) · The Journal of Pathology · doi:10.1002/path.4550 · Cited by 132
“The EMT signature is related to increased expression of well known EMT-TFs (ZEB1, PRRX1) and decreased expression of MET-TFs (OVOL1, KLFs, and GRHLs), in addition to most of the miR-200 family members [33].”
BackgroundEpigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties
Taube, J. H., Malouf, G. G., Lu, E., Sphyris, N., Vijay, G. V., Ramachandran, P. P., Ueno, K. R., Gaur, S., Nicoloso, M. S., Rossi, S., et al. (2013) · Scientific Reports · doi:10.1038/srep02687 · Cited by 136
EMT and Stemness in Tumor Dormancy and Outgrowth: Are They Intertwined Processes?
Weidenfeld, K., & Barkan, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00381 · Cited by 129
“Snail, Slug, Zeb1 and Twist1 are some of the transcription factors that repress epithelial adhesion protein such as E-cadherin (EMT-TF) and were shown to orchestrate EMT programming (24, 25).”
BackgroundCarcinoma-associated fibroblasts provide operational flexibility in metastasis
Wever, O. D., Bockstal, M. V., Mareel, M., Hendrix, A., & Bracke, M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.009 · Cited by 151
Liao, T., & Yang, M. (2020) · Cells · doi:10.3390/cells9030623 · Cited by 150
“Beyond allowing epithelial cancer cells to acquire migratory and invasive characteristics, EMT also overcomes senescence, apoptosis, and anoikis, which are essential properties for cancer dissemination and metastasis [5].”
BackgroundAllgayer, H., Mahapatra, S., Mishra, B., Swain, B., Saha, S., Khanra, S., Kumari, K., Panda, V. K., Malhotra, D., Patil, N. S., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02338-2 · Cited by 127
“It has been linked to an array of cancer characteristics, which involve tumor initiation, intravasation into vessels, tumor cell migration, cancer cell stemness, metastasis, and therapeutic resistance [1, 6, 7].”
MiRNA-mediated EMT and CSCs in cancer chemoresistance
Dong, B., Li, S., Zhu, S., Yi, M., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00206-5 · Cited by 129
“These transcription factors are termed as EMTinducing transcription factors (EMT-TFs), which are typically categorized into three different protein families, including the ZEB (ZEB1 and ZEB2), Snail (SNAI1 and SNAI2, also termed as Snail and Slug), and basic helix– loop–helix (Twist1 and Twist2) families [18].”
BackgroundSynergistic action of master transcription factors controls epithelial-to-mesenchymal transition
Chang, H., Liu, Y., Xue, M., Liu, H., Du, S., Zhang, L., & Wang, P. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw126 · Cited by 127
“Currently, more than 30 TFs have been implicated in EMT programs underlying a variety of tissue remodeling events (1,2).”
BackgroundEpithelial‐to‐mesenchymal‐like transition events in melanoma
Pedri, D., Karras, P., Landeloos, E., Marine, J., & Rambow, F. (2022) · The FEBS Journal · doi:10.1111/febs.16021 · Cited by 126
EMT transcription factors: implication in osteosarcoma
Yang, G., Yuan, J., & Li, K. (2013) · Medical Oncology · doi:10.1007/s12032-013-0697-2 · Cited by 130
The emerging role of SPOP protein in tumorigenesis and cancer therapy
Song, Y., Xu, Y., Pan, C., Yan, L., Wang, Z. P., & Zhu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1124-x · Cited by 134
Trophoblast invasion: Lessons from abnormally invasive placenta (placenta accreta)
Illsley, N. P., DaSilva‐Arnold, S. C., Zamudio, S., Alvarez, M., & Al‐Khan, A. (2020) · Placenta · doi:10.1016/j.placenta.2020.01.004 · Cited by 130
“As part of the analysis of EMT genes, we analyzed the expression of multiple EMT “master regulator” transcription factors (FOXC2, GSC, TWIST1, SNA1, SNA2, ZEB1, ZEB2) [50,51].”
BackgroundLai, X., Li, Q., Wu, F., Lin, J., Chen, J., Zheng, H., & Guo, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00760 · Cited by 143
Lucena, M. C., Carvalho-Cruz, P., Donadio, J. L., Oliveira, I. A., de Queiroz, R. M., Marinho-Carvalho, M. M., Sola-Penna, M., de Paula, I. F., Gondim, K. C., McComb, M. E., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.729236 · Cited by 123
“The EMT is well documented to play a critical role in tumor invasion and metastasis (19-21).”
BackgroundLiang, W., Ren, J.-L., Wong, C.-W., Chan, S. O., Waye, M. M. Y., Fu, W.-M., & Zhang, J. (2018) · Oncogene · doi:10.1038/s41388-017-0041-y · Cited by 125
Zhou, Z., Xia, G., Xiang, Z., Liu, M., Wei, Z., Yan, J., Chen, W., Zhu, J., Awasthi, N., Sun, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3567 · Cited by 141
A Smart Theranostic Nanocapsule for Spatiotemporally Programmable Photo‐Gene Therapy
Gong, X. Q., Li, R., Wang, J., Wei, J., Ma, K., Liu, X., & Wang, F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202008413 · Cited by 123
Differences and similarities between cancer and somatic stem cells: therapeutic implications
Rossi, F., Noren, H., Jove, R., Beljanski, V., & Grinnemo, K.-H. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02018-6 · Cited by 121
Cancer metastasis: Molecular mechanisms and clinical perspectives
Khan, S. U., Fatima, K., Malik, F. A., Kalkavan, H., & Wani, A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108522 · Cited by 132
Interaction between circulating cancer cells and platelets: clinical implication.
Lou, X., Sun, J., Gong, S.-Q., Yu, X., Gong, R., & Deng, H. (2015) · Chinese Journal of Cancer Research · doi:10.3978/j.issn.1000-9604.2015.04.10 · Cited by 158
“Inhibition of EMT-related signaling elements, such as Twist, Zeb and Snail, can prevent metastatic relapse (122).”
Zhao, T., Zhu, Y., Morinibu, A., Kobayashi, M., Shinomiya, K., Itasaka, S., Yoshimura, M., Guo, G., Hiraoka, M., & Harada, H. (2014) · Scientific Reports · doi:10.1038/srep03793 · Cited by 120
“(c–e) EMT6/CMVp-CLuc/5HREp-FLuc cells were cultured with (1) or without (2) N-”
MethodMarkers of pancreatic cancer stem cells and their clinical and therapeutic implications
Gzil, A., Zarębska, I., Bursiewicz, W., Antosik, P., Grzanka, D., & Szylberg, Ł. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-05058-1 · Cited by 124
“The standard CD44 isoform (CD44s) is composed of exons 1–5 and 16–20, thus it is called the constant form.”
BackgroundInfluentialSIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors
Malik, S., Villanova, L., Tanaka, S., Aonuma, M., Roy, N., Berber, E., Pollack, J. R., Michishita-Kioi, E., & Chua, K. F. (2015) · Scientific Reports · doi:10.1038/srep09841 · Cited by 125
Regulation of hyaluronan biosynthesis and clinical impact of excessive hyaluronan production
Heldin, P., Lin, C., Kolliopoulos, C., Chen, Y., & Skandalis, S. S. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.01.017 · Cited by 128
Insights Into Amentoflavone: A Natural Multifunctional Biflavonoid
Xiong, X., Tang, N., Lai, X., Zhang, J., Wen, W., Li, X., Li, A., Wu, Y., & Liu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.768708 · Cited by 132
Boareto, M., Jolly, M. K., Goldman, A., Pietilä, M., Mani, S. A., Sengupta, S., Ben-Jacob, E., Levine, H., & Onuchic, J. N. (2016) · Journal of The Royal Society Interface · doi:10.1098/rsif.2015.1106 · Cited by 123
“Within individual cells, the decision as to whether cells remain epithelial, undergo partial EMT or complete EMT is mediated by various signalling pathways [6,7].”
BackgroundFrom neural crest cells to melanocytes: cellular plasticity during development and beyond
Vandamme, N., & Berx, G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03049-w · Cited by 146
Self-citationSung, W., Lin, Y., Wu, P., Yen, H., Lai, H., Su, T., Huang, R.-H., Wen, C.-K., Chen, C., Chen, C., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-951 · Cited by 130
“Successful metastasis requires that the cancer cells enter the blood circulation, attach to the endothelium, invade the target distant organs, and subsequently form tumors [3,4].”
BackgroundEpithelial–mesenchymal plasticity and circulating tumor cells: Travel companions to metastases
Francart, M., Lambert, J., Vanwynsberghe, A. M., Thompson, E. W., Bourcy, M., Polette, M., & Gilles, C. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24506 · Cited by 125
“These EMT core molecular actors have been reviewed elsewhere (Kalluri and Weinberg, 2009; De Craene and Berx, 2013; Tsai and Yang, 2013; Lamouille et al., 2014; Jolly et al., 2015b; Nieto et al., 2016) and will, therefore, not be detailed here.”
Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
Marques, P., Barry, S., Carlsen, E., Collier, D., Ronaldson, A., Awad, S., Dorward, N., Grieve, J., Mendoza, N., Muquit, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0830-3 · Cited by 131
Oncogenic Alternative Splicing Switches: Role in Cancer Progression and Prospects for Therapy
Bonomi, S., Gallo, S., Catillo, M., Pignataro, D. S., Biamonti, G., & Ghigna, C. (2013) · International Journal of Cell Biology · doi:10.1155/2013/962038 · Cited by 135
“The first example of alternative splicing was discovered almost 30 years ago, when membrane-bound and secreted antibodies were demonstrated to be encoded by the same gene [1, 2].”
BackgroundNakano, M., Kikushige, Y., Miyawaki, K., Kunisaki, Y., Mizuno, S., Takenaka, K., Tamura, S., Okumura, Y., Ito, M., Ariyama, H., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0480-0 · Cited by 125
Matsuzaki, S., Klar, M., Matsuzaki, S., Roman, L. D., Sood, A. K., & Matsuo, K. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.10.043 · Cited by 140
IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella
Lin, Q., Li, R., Jia, X., Li, R., Yu, B., Hu, J., Luo, X., Badea, S. R., Chen, X., Fu, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22755-3 · Cited by 126
Ren, X., Liang, J., Zhang, Y., Jiang, N., Xu, Y., Qiu, M., Wang, Y., Zhao, B. T., & Chen, X. (2022) · Nature Communications · doi:10.1038/s41467-022-33982-7 · Cited by 130
Goel, H. L., Gritsko, T., Pursell, B., Chang, C., Shultz, L. D., Greiner, D. L., Norum, J. H., Toftgard, R., Shaw, L. M., & Mercurio, A. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.059 · Cited by 114
“Our data also impact the emerging importance of alternative RNA splicing to the EMT and stem cell biology (Brown et al., 2011; De Craene and Berx, 2013; Han et al., 2013; Shapiro et al., 2011; Warzecha et al., 2010; Yae et al., 2012).”
BackgroundMicroRNA Regulation of Epithelial to Mesenchymal Transition
Abba, M. L., Patil, N., Leupold, J. H., & Allgayer, H. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5010008 · Cited by 120
“The process encompasses a form of epithelial plasticity that is characterized by both morphological and molecular changes in epithelial cells [2–6].”
BackgroundLOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway
Cuevas, E. P., Eraso, P., Mazón, M. J., Santos, V., Moreno‐Bueno, G., Cano, A., & Portillo, F. (2017) · Scientific Reports · doi:10.1038/srep44988 · Cited by 131
Sjöberg, E., Meyrath, M., Milde, L., Herrera, M., Lövrot, J., Hägerstrand, D., Frings, O., Bartish, M., Rolny, C., Sonnhammer, E. L. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1294 · Cited by 135
“Activation of these factors ultimately leads to the loss of epithelial markers including E-cadherin and cytokeratins, and the upregulation of mesenchymal markers, such as vimentin, alphasmoothmuscle actin (aSMA), andmatrix-degrading enzymes (3).”
BackgroundEnhancer methylation dynamics contribute to cancer plasticity and patient mortality
Bell, R. E., Golan, T., Sheinboim, D., Malcov, H., Amar, D., Salamon, A., Liron, T., Gelfman, S., Gabet, Y., Shamir, R., et al. (2016) · Genome Research · doi:10.1101/gr.197194.115 · Cited by 117
“The transition of cancer from the in situ primary stage to the metastatic stage involves phenotypic plasticity (Craene and Berx 2013), which facilitates migration through tissues and adaptation”
MicroRNA-194 Promotes Prostate Cancer Metastasis by Inhibiting SOCS2
Das, R., Gregory, P. A., Fernandes, R. C., Denis, I., Wang, Q., Townley, S. L., Zhao, S. G., Hanson, A. R., Pickering, M. A., Armstrong, H. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2529 · Cited by 117
“50),MAP4K4 (39), the EMT-promoting transcription factor Bmi-1 (51), and the oncogenic transcription factor YAP1 (52).”
BackgroundInfluentialCancer metastasis - tricks of the trade
Zeeshan, R., & Mutahir, Z. (2017) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2017.1908 · Cited by 138
Huang, R., & Zong, X. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.005 · Cited by 120
Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression
Rokavec, M., Kaller, M., Horst, D. A., & Hermeking, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04234-2 · Cited by 121
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 127
Miyake, M., Hori, S., Morizawa, Y., Tatsumi, Y., Toritsuka, M., Ohnishi, S., Shimada, K., Furuya, H., Khadka, V. S., Deng, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16432 · Cited by 120
“Previous studies demonstrated that EMT-inducing signaling pathways including TGF-β and Wnt/β-catenin were activated in tumor budding [17].”
BackgroundResultRole of extracellular matrix in breast cancer development: a brief update
Jena, M. K., & Janjanam, J. (2018) · F1000Research · doi:10.12688/f1000research.14133.1 · Cited by 134
Mancarella, S., Cigliano, A., Chieti, A., Giannelli, G., & Dituri, F. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676121 · Cited by 115
Li, S., Zhang, J., Qian, S., Wu, X., Sun, L., Ling, T., Jin, Y., Li, W., Sun, L., Lai, M., et al. (2021) · 癌症:英文版 · doi:10.1002/cac2.12130 · Cited by 128
“In tumors, EMT provides malignant cells with stronger metastatic ability regulated by the complex networks between tumor cells and the tumormicroenvironment [8].”
BackgroundChoi, H., Park, J., Park, M., Won, H., Joo, H.-S., Lee, C. H., Lee, J., & Kong, G. (2015) · EMBO Reports · doi:10.15252/embr.201540244 · Cited by 124
“Epigenetic changes occur in the CDH1 promoter during the EMT through the cooperation of various epigenetic regulators (such as histone methyltransferases, HDACs and DNMTs) with EMT-TFs [6,25,26,30].”
miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3
Boufraqech, M., Zhang, L., Jain, M., Patel, D., Ellis, R. J., Xiong, Y., He, M., Nilubol, N., Merino, M. J., & Kebebew, E. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0077 · Cited by 120
“2005, Patel & Shaha 2006), which is accompanied by altered cellular morphology and increased cell spreading (De Craene & Berx 2013).”
BackgroundYang, Y., Zhang, Y., Iwamoto, H., Hosaka, K., Seki, T., Andersson, P., Lim, S., Fischer, C., Nakamura, M., Abe, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12680 · Cited by 112
Jia, Y., Duan, Y., Liu, T., Wang, X., Lv, W., Wang, M., Wang, J., & Liu, L. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1811-y · Cited by 121
Yang, Q., Huang, J., Wu, Q., Cai, Y., Zhu, L., Lu, X., Chen, S., Chen, C., & Wang, Z. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.136 · Cited by 115
“Epithelial–mesenchymal transition is a complex process by which epithelial cells transit to mesenchymal phenotype through loss of epithelial cell–cell junction and actin cytoskeleton reorganisation (De Craene and Berx, 2013).”
BackgroundOrecchioni, S., Gregato, G., Martin-Padura, I., Reggiani, F., Braidotti, P., Mancuso, P., Calleri, A., Quarna, J., Marighetti, P., Aldeni, C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0821 · Cited by 111
Ma, X., Sun, P., & Qin, G. (2017) · Pattern Recognition · doi:10.1016/j.patcog.2017.06.025 · Cited by 119
Prospects for new lung cancer treatments that target EMT signaling
Otsuki, Y., Saya, H., & Arima, Y. (2017) · Developmental Dynamics · doi:10.1002/dvdy.24596 · Cited by 117
“, 2012) as well as with the formation of cancer stem cells and drug resistance (Byers et al., 2013; Craene and Berx, 2013) in NSCLC.”
BackgroundMesogenin 1 is a master regulator of paraxial presomitic mesoderm differentiation
Chalamalasetty, R. B., Garriock, R. J., Dunty, W. C., Kennedy, M. W., Jailwala, P., Si, H., & Yamaguchi, T. P. (2014) · Development · doi:10.1242/dev.110908 · Cited by 120
Competitive endogenous RNA is an intrinsic component of EMT regulatory circuits and modulates EMT
Liu, Y., Xue, M., Du, S., Feng, W.-W., Zhang, K., Zhang, L., Liu, H., Jia, G., Wu, L., Hu, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09649-1 · Cited by 117
Role of microRNAs in chemoresistance.
Magee, P., Shi, L., & Garofalo, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.11.32 · Cited by 70
“During EMT transformed epithelial cells can acquire the abilities for tumour invasion and metastasis, resist apoptosis, and disseminate (49).”
BackgroundTumor-educated mesenchymal stem cells promote pro-metastatic phenotype
Hill, B. S., Pelagalli, A., Passaro, N., & Zannetti, A. (2017) · Oncotarget · doi:10.18632/oncotarget.20265 · Cited by 104
“It has been reported the importance of expression and functional activation of a group of EMT-inducing transcription factors (Twist, Snail, Slug, zinc finger E-box-binding homeobox 1 (ZEB1) and ZEB2 [81, 94].”
BackgroundWu, D.-M., Zhang, T., Liu, Y.-B., Deng, S.-H., Han, R., Liu, T., Li, J., & Xu, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1591-4 · Cited by 109
TRIM21 – A potential novel therapeutic target in cancer
Alomari, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105443 · Cited by 120
Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., Wang, X., Liu, Y., Xu, N., Yan, X., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3563 · Cited by 109
“Emerging evidence indicates a strong link between resistance to chemotherapy and the induction of epithelial-mesenchymal transition (EMT) in cancer [4].”
Novel biological insights in T-cell acute lymphoblastic leukemia
Durinck, K., Goossens, S., Peirs, S., Wallaert, A., Loocke, W. V., Matthijssens, F., Pieters, T., Milani, G., Lammens, T., Rondou, P., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.017 · Cited by 123
“The zinc finger E-box binding homeobox 2 protein (ZEB2/ SIP1) has an established role in the process of epithelialmesenchymal transition (EMT) and is implicated in both normal embryonic development and tumorigenesis [48] such as melanoma [49], breast [50], and gastric cancer [51].”
BackgroundEZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway
Murai, F., Koinuma, D., Shinozaki‐Ushiku, A., Fukayama, M., Miyaozono, K., & Ehata, S. (2015) · Cell Discovery · doi:10.1038/celldisc.2015.26 · Cited by 114
Song, Y., Zheng, S., Wang, J., Long, H., Fang, L., Wang, G., Li, Z., Que, T., Liu, Y., Li, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16710 · Cited by 116
The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
Mei, W., Lin, X., Kapoor, A., Gu, Y. J., Zhao, K., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11040434 · Cited by 115
“It has been recently reported that the ZEB1–miR375–YAP1 pathway promotes PC metastasis via regulating EMT and MET; while ZEB1 induces EMT, miR375 initiates MET via the inhibition of YAP1 expression in PC [110].”
BackgroundInfluentialMolecular regulation of Snai2 in development and disease
Zhou, W., Gross, K. M., & Kuperwasser, C. (2019) · Journal of Cell Science · doi:10.1242/jcs.235127 · Cited by 120
Dissecting miRNA signature in colorectal cancer progression and metastasis
Huang, X., Zhu, X., Yu, Y., Zhu, W., Jin, L., Zhang, X., Li, S., Zou, P., Xie, C., & Cui, R. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.025 · Cited by 114
SOX9: An emerging driving factor from cancer progression to drug resistance
Panda, M., Tripathi, S. K., & Biswal, B. K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188517 · Cited by 115
The Role of the IL-6 Cytokine Family in Epithelial–Mesenchymal Plasticity in Cancer Progression
Abaurrea, A., Araujo, A. M., & Caffarel, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158334 · Cited by 117
An emerging role for long non-coding RNAs in cancer metastasis
Serviss, J. T., Johnsson, P., & Grandér, D. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00234 · Cited by 116
“Furthermore, alternative splicing, post-transcriptional regulation, and microRNAs (miRNA) have all been shown to be important mechanisms in the regulation of EMT (reviewed in De Craene and Berx, 2013).”
BackgroundPaltoglou, S., Das, R., Townley, S. L., Hickey, T. E., Tarulli, G. A., Coutinho, I., Fernandes, R., Hanson, A. R., Denis, I., Carroll, J. S., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1616 · Cited by 112
“EMT has been demonstrated to play a key role in certain phases of metastasis, including escape from the primary tumor, migration and invasion into the stroma, entry/exit from the bloodstream and suppression of senescence, apoptosis and anoikis (39).”
BackgroundSong, Y., Wang, R., Li, L.-W., Liu, X., Wang, Y., Wang, Q., & Zhang, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4625 · Cited by 121
“Epithelial-to-mesenchymal transition (EMT) is a multi-step process that converts epi thelial cells into mesenchymal cells, which is mediated by series of transcription factors (TFs) (1).”
Zhang, L., Song, X., Chen, X., Wang, Q., Zheng, X., Wu, C., & Jiang, J. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.31533 · Cited by 113
“EMT is a cellular reprogramming process in which epithelial cells visibly alter their shape, acquire a mesenchymal phenotype and exhibit increased motility, and this cellular change is essential for tumor metastasis[24, 25].”
BackgroundZhang, M., Hoyle, R. G., Ma, Z., Sun, B., Cai, W., Cai, H., Xie, N., Zhang, Y., Hou, J., Liu, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.024 · Cited by 121
High expression of small GTPase Rab3D promotes cancer progression and metastasis
Yang, J., Liu, W., Lu, X., Fu, Y., Li, L., & Luo, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3575 · Cited by 107
“EMT is the key player during tumor metastasis, in which E-cadherin is down-regulated and N-cadherin is increased [48, 49].”
BackgroundLysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer
Hashimoto, S., Mikami, S., Sugino, H., Yoshikawa, A., Hashimoto, A., Onodera, Y., Furukawa, S., Handa, H., Oikawa, T., Okada, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms10656 · Cited by 107
Campbell, K., Rossi, F., Adams, J., Pitsidianaki, I., Barriga, F. M., Garcia-Gerique, L., Batlle, E., Casanova, J., & Casali, A. (2019) · Nature Communications · doi:10.1038/s41467-019-10269-y · Cited by 116
A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer
Selth, L. A., Das, R., Townley, S. L., Coutinho, I., Hanson, A. R., Centenera, M. M., Stylianou, N., Sweeney, K. G., Soekmadji, C., Jovanovic, L., et al. (2016) · Oncogene · doi:10.1038/onc.2016.185 · Cited by 106
Contribution of epithelial-mesenchymal transitions to organogenesis and cancer metastasis
Campbell, K. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.06.008 · Cited by 111
Chakraborty, P., George, J. T., Tripathi, S., Levine, H., & Jolly, M. K. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00220 · Cited by 129
Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.
Darwiche, N. (2020) · PubMed · Cited by 163
G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells
Rao, A., & Herr, D. R. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.05.001 · Cited by 104
Zhou, Z., Dai, Z., Zhou, S., Hu, Z., Chen, Q., Zhao, Y., Shi, Y., Gao, Q., Wu, W., Qiu, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2509 · Cited by 103
“Important advances in our understanding of the posttranscriptional regulatory mechanisms of SNAIL have been reported (9, 40).”
BackgroundDong, T., Zhang, Y., Chen, Y., Liu, P., An, T., Zhang, J., Yang, H., Zhu, W., & Yang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13786 · Cited by 112
Xia, H., Chen, J., Shi, M., Gao, H., Sekar, K., Seshachalam, V. P., Ooi, L. L., & Hui, K. M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.005 · Cited by 105
“migratory and invasive properties to become mesenchymal cells [7-9].”
He, X., Yan, B., Liu, S., Jia, J., Lai, W., Xing, X., Tang, C., Luo, D., Tan, T., Jiang, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0268 · Cited by 112
“The metabolic reprogramming that is associated with EMT demands fundamental changes of regulatory networks (16).”
Background
Metadata
- Authors
- Craene, B. D., & Berx, G.
- Affiliations
- Ghent University (BE)
- Vlaams Instituut voor Biotechnologie (BE)
- Corresponding author
- Berx, Geert
- ORCID
- Berx, Geert
- Venue
- Nature Reviews Cancer
- Published
- 2013-01-24
- Volume
- 13
- Issue
- 2
- Pages
- 97-110
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2016360721
- Cited by
- 2,487
- References
- 205
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 127 · 2023: 159 · 2022: 209 · 2021: 247 · 2020: 260 · 2019: 239 · 2018: 234 · 2017: 253 · 2016: 202 · 2015: 181 · 2014: 182 · 2013: 83
- FWCI
- 22.16
- Type
- journal article
- Language
- en
- Open access
- green
- zenodo.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Funders
- Cancer Research UK
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- epithelial-mesenchymal transition, tumor progression, tumor initiation, cellular plasticity, transcriptional regulation, translational regulation, non-coding RNA, alternative splicing, protein stability
- MeSH terms
- Animals, Epithelial Cells, Humans, Neoplasms, Disease Progression, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.